ALK and non-small cell lung carcinoma: Based on these trials, recent recommendations from the American Society of Clinical Oncology (ASCO) and Ontario Health (OH; Cancer Care Ontario) consider ICI ± chemotherapy as the standard of care for treatment-naïve EGFR and ALK-negative stage IV NSCLC [92].